<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="" /><meta name="keywords" content="Alkylating drugs; Cyclophosphamide; Acrolein; Mesna; Ifosfamide; Chlorambucil; Melphalan; Busulfan; Busulphan see Busulfan; Leukaemia: chronic myeloid; Lomustine; Bendamustine; Carmustine; Estramustine; Prostate cancer: estramustine; Treosulfan; Thiotepa; Mitobronitol" /><meta name="IX" content="Alkylating drugs; Cyclophosphamide; Acrolein; Mesna; Ifosfamide; Chlorambucil; Melphalan; Busulfan; Leukaemia: chronic myeloid; Lomustine; Bendamustine; Carmustine; Estramustine; Prostate cancer: estramustine; Treosulfan; Thiotepa; Mitobronitol" /><meta name="IXN" content="Busulphan see Busulfan" /><title>8.1.1 Alkylating drugs: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../383/theme.css" /><link type="text/css" rel="stylesheet" href="204/style.css" /><link type="image/x-icon" rel="shortcut icon" href="../../favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP5236-alkylating-drugs.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.8/jquery.min.js"></script><script type="text/javascript" src="../../383/scripts.js"></script><style type="text/css">
          .contentsbox { position: fixed; z-index:1001; }
          .contentsbox_wrap { overflow: hidden; width: 20px; height: 130px; position: absolute; left: 0; top: 0; }
        </style><!--[if IE 8]>
          <style type="text/css">
          #p1 {
          float: left;
          padding-bottom: 15em;
          }
          </style>
          <![endif]--><!--[if lte IE 8]>
          <style type="text/css">
          #start-search input {
          height: 28px;
          padding-top: 8px;
          }
          @media screen {
          #pV {
          display: block !important;
          }
          }
          </style>
          <![endif]--><!--[if IE 7]>
          <style type="text/css">
          #start-search input {
          position: absolute !important;
          left: 0;
          top: 0;
          }
          .as-shadow {
          margin-left: -4px !important;
          color: silver;
          }
          </style>
          <![endif]--><!--[if lte IE 7]>
          <style type="text/css">
          .menu {
          height: 1%;
          }
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }

          #account-info ul li a {
          width: 12em;
          }
          #opts ul li span {
          width: 12em;
          }
          div.as-select ul li ul li span {
          width: 40em;
          }
          div.menu ul li ul li {
          float: left !important;
          }
          #pQ fieldset, #qd, #input-box, #pub-list, #start-search, #end-search {
          display: inline;
          float: left;
          height: 100%;
          padding: 0;
          margin: 0;
          position: relative;
          }
          #hM a, #hM a img {
          border: none;
          display: inline-block;
          float: left;
          }
          #qd input {
          float: left;
          display: inline-block !important;
          }
          #start-search input {
          height: 28px;
          padding-top: 8px !important;
          }
          #end-search, #end-search input {
          height: 36px !important;
          }
          #hM, #content, #searchForm, #purple-menu {
          width: expression(document.body.clientWidth > 63 * parseInt(document.body.currentStyle.fontSize) ? '63em': 'auto');
          margin: 0 auto;
          }
          #pQ {
          z-index: 1;
          }
          </style>
          <![endif]--><!--[if lte IE 6]>
          <style type="text/css">
          body {
          height: 100%;
          }
          div.menu ul li a, div.menu ul li span {
          display: inline-block;
          }
          div.menu ul li ul li {
          clear: both;
          }
          div.as-select ul li span {
          height: 20px;
          padding-top: 16px;
          padding-left: 1em;
          padding-bottom: 0;
          padding-left: 1em;
          margin: 4px 0;
          border-right: 1px solid #888;
          background-image: url("images/dropdown_img.png");
          background-repeat: repeat-x;
          overflow-x: hidden;
          }
          div.as-select ul li ul li span {
          font: bold 10px Verdana !important;
          padding: 4px 1em !important;
          color: #2D2D2D;
          background: white;
          text-decoration: none !important;
          white-space: nowrap;
          border: none !important;
          float: left;
          }
          div.menu span.hover {
          background: #8F1F8D;
          color: white;
          }
          </style>
          <![endif]--></head><body><!--[if lte IE 6]>
          <script type="text/javascript">
          jQuery(document).ready(function($) {
          $('a.mclogo').html('<img src="images/mc_logo.gif" class="logo" />');
          });
          </script>
          <![endif]--><?highlighter off?><div id="hC"><div id="vH"><div id="pU"><a class="mclogo" href="http://www.medicinescomplete.com/about/"><img class="logo" src="../../images/mc_logo.png" alt="MedicinesComplete" /></a><div id="hM"><div id="vM" class="menu"><ul><li><a href="http://www.medicinescomplete.com/mc/index.htm">Home</a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm">Help</a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP5236-alkylating-drugs.htm">Feedback</a></li><li id="account-info"><a href="http://www.medicinescomplete.com/mc/account.htm">BNF.org Free Access</a><ul><li><a href="http://www.medicinescomplete.com/mc/account.htm">My Account</a></li><li><a href="http://www.medicinescomplete.com/mc/subscribe.htm">Subscribe</a></li><li><a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li><a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul></li></ul></div><a id="pD" accesskey="s" rel="bookmark" href="PHP5236-alkylating-drugs.htm#pB" title="Skip Navigation">Skip Navigation</a></div></div><div id="pA"><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 13 Mar 2013 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="search-in">Publication</label><label for="q">Search for</label><div id="qd"><div id="start-search"><div class="as-select menu" id="pub-list"><ul><li><span>British National Formulary</span><ul></ul></li></ul></div><div id="input-box"><input type="text" id="q" name="q" accesskey="4" /></div></div><div id="end-search"><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div></div></div><div id="pH"><div id="pN"><div id="pT"><!--[if lte IE 7]>
             
            <![endif]--><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF March 2013</a> &gt; <a href="PHP5179-malignant-disease-and-immunosuppression.htm">8 Malignant disease and immunosuppression</a> &gt; <a href="PHP5180-cytotoxic-drugs.htm">8.1 Cytotoxic drugs</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP5234-mesna.htm" title="Previous: MESNA">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP5253-bendamustine-hydrochloride.htm" title="Next: BENDAMUSTINE HYDROCHLORIDE">Next page</a> ►</div></div></div></div><div id="content"><div id="p1"><div id="pB"><?highlighter on?><h1><span>8.1.1 </span>Alkylating drugs</h1><?highlighter off?><?highlighter on?><div id="pC" class="jN"><p>Extensive experience is available with these drugs, which are among the most widely used in cancer chemotherapy. They act by damaging DNA, thus interfering with cell replication. In addition to the side-effects common to many cytotoxic drugs (<a title="topic: Side-effects of cytotoxic drugs" href="PHP5183-side-effects-of-cytotoxic-drugs.htm">section 8.1</a>), there are two problems associated with prolonged usage. Firstly, gametogenesis is often severely affected (<a title="target-block: Cytotoxic drugs: Reproductive function" href="PHP5183-side-effects-of-cytotoxic-drugs.htm#PHP5194">section 8.1</a>). Secondly, prolonged use of these drugs, particularly when combined with extensive irradiation, is associated with a marked increase in the incidence of acute non-lymphocytic leukaemia.</p><p id="PHP5238"><strong>Cyclophosphamide</strong> is used mainly in combination with other agents for treating a wide range of malignancies, including some leukaemias, lymphomas, and solid tumours. It is given by mouth or intravenously; it is inactive until metabolised by the liver. A urinary metabolite of cyclophosphamide, acrolein, can cause haemorrhagic cystitis; this is a rare but serious complication; increased fluid intake for 24–48 hours after intravenous injection, can prevent this complication. When high-dose therapy (e.g. more than 2 g intravenously) is used or when the patient is considered to be at high risk of cystitis (e.g. because of pelvic irradiation), mesna (given initially intravenously then by mouth) can also help prevent cystitis—see under Urothelial Toxicity (<a title="BNF:monograph-family: Urothelial toxicity" href="PHP5233-urothelial-toxicity.htm">section 8.1</a>).</p><p id="PHP5240"><strong>Ifosfamide</strong> is related to cyclophosphamide and is given intravenously; mesna (<a title="BNF:monograph-family: Urothelial toxicity" href="PHP5233-urothelial-toxicity.htm">section 8.1</a>) is routinely given with it to reduce urothelial toxicity.</p><p id="PHP5241"><strong>Chlorambucil</strong> is used either alone or in combination therapy for some lymphomas and chronic leukaemias. It is given by mouth. Side-effects, apart from bone-marrow suppression, are uncommon. However, patients occasionally develop severe widespread rashes which can progress to Stevens-Johnson syndrome or to toxic epidermal necrolysis. If a rash occurs further chlorambucil is contra-indicated and cyclophosphamide is substituted. </p><p id="PHP5243"><strong>Melphalan</strong> is licensed for the treatment of multiple myeloma, polycythaemia vera, childhood neuroblastoma, advanced ovarian adenocarcinoma, and advanced breast cancer. However, in practice, melphalan is rarely used for ovarian adenocarcinoma; it is no longer used for advanced breast cancer. Melphalan is also licensed for regional arterial perfusion in localised malignant melanoma of the extremities and localised soft-tissue sarcoma of the extremities. Interstitial pneumonitis and life-threatening pulmonary fibrosis are rarely associated with melphalan.</p><p id="PHP5244"><strong>Busulfan </strong>is given by mouth to treat chronic myeloid leukaemia. Busulfan given by mouth or intravenously, followed by cyclophosphamide, is also licensed as conditioning treatment before haematopoietic stem-cell transplantation in adults and children. Frequent blood tests are necessary because excessive myelosuppression may result in irreversible bone-marrow aplasia. Rarely, progressive pulmonary fibrosis is associated with busulfan. Skin hyperpigmentation is a common side-effect of oral therapy.</p><p id="PHP5246"><strong>Lomustine</strong> is a lipid-soluble nitrosourea and is given by mouth. It is used mainly to treat Hodgkin's disease resistant to conventional therapy, malignant melanoma and certain solid tumours. Bone-marrow toxicity is delayed, and the drug is therefore given at intervals of 4 to 6 weeks. Permanent bone-marrow damage can occur with prolonged use. Nausea and vomiting are common and moderately severe.</p><p id="PHP5248"><strong>Bendamustine</strong> given intravenously is licensed for the treatment of chronic lymphocytic leukaemia, non-Hodgkin's lymphoma, and for the treatment of multiple myeloma. </p><p>The <a title="BNF:target-block: NICE and Scottish Medicines Consortium" href="PHP60-general-guidance.htm#PHP70"><em>Scottish Medicines Consortium</em></a> has advised (March 2011) that bendamustine (<em>Levact</em>®) is accepted for restricted use within NHS Scotland for the treatment of chronic lymphocytic leukaemia in patients for whom fludarabine combination chemotherapy is not appropriate.</p><div id="PHP19192" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Bendamustine for the first-line treatment of chronic lymphocytic leukaemia (February 2011)</h3><p>Bendamustine is recommended as an option for the treatment of chronic lymphocytic leukaemia in patients for whom fludarabine combination chemotherapy is not appropriate.</p><p><a href="http://www.nice.org.uk/TA216">www.nice.org.uk/TA216</a></p></div><p id="PHP5249"><strong>Carmustine</strong> given intravenously has similar activity to lomustine; it is given to patients with multiple myeloma, non-Hodgkin's lymphomas, and brain tumours. Cumulative renal damage and delayed pulmonary fibrosis may occur with intravenous use. Carmustine implants are licensed for intralesional use in adults for the treatment of recurrent glioblastoma multiforme as an adjunct to surgery. Carmustine implants are also licensed for high-grade malignant glioma as adjunctive treatment to surgery and radiotherapy.</p><div class="cI"><h3 class="cT">NICE guidance (carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma)</h3><p>See   <a title="target-block: Carmustine implants and temozolomide - high grade glioma" href="PHP5459-dacarbazine-and-temozolomide.htm#PHP5460">Dacarbazine and Temozolomide</a></p></div><p><strong>Estramustine</strong> is a combination of an oestrogen and chlormethine used predominantly in prostate cancer. It is given by mouth and has both an antimitotic effect and (by reducing testosterone concentration) a hormonal effect.</p><p id="PHP5251"><strong>Treosulfan</strong> is given by mouth or by intravenous or intraperitoneal administration and is used to treat ovarian cancer. Skin pigmentation is a common side-effect and allergic alveolitis, pulmonary fibrosis and haemorrhagic cystitis occur rarely.</p><p id="PHP5252"><strong>Thiotepa</strong> is licensed in combination with other chemotherapy as conditioning treatment in adults and children with haematological disease or solid tumours before haematopoietic stem cell transplantation.</p><p><strong>Mitobronitol</strong> is occasionally used to treat chronic myeloid leukaemia; it is available on a named-patient basis from <a title="BNF:appendix: Special-order Manufacturers" href="PHP10403-special-order-manufacturers.htm">specialist importing companies</a>.</p></div><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_PHP5253-bendamustine-hydrochloride"><a href="PHP5253-bendamustine-hydrochloride.htm" title="BENDAMUSTINE HYDROCHLORIDE">BENDAMUSTINE HYDROCHLORIDE</a></li><li id="_PHP5255-busulfan"><a href="PHP5255-busulfan.htm" title="BUSULFAN">BUSULFAN</a></li><li id="_PHP5259-carmustine"><a href="PHP5259-carmustine.htm" title="CARMUSTINE">CARMUSTINE</a></li><li id="_PHP5261-chlorambucil"><a href="PHP5261-chlorambucil.htm" title="CHLORAMBUCIL">CHLORAMBUCIL</a></li><li id="_PHP5265-cyclophosphamide"><a href="PHP5265-cyclophosphamide.htm" title="CYCLOPHOSPHAMIDE">CYCLOPHOSPHAMIDE</a></li><li id="_PHP5268-estramustine-phosphate"><a href="PHP5268-estramustine-phosphate.htm" title="ESTRAMUSTINE PHOSPHATE">ESTRAMUSTINE PHOSPHATE</a></li><li id="_PHP5270-ifosfamide"><a href="PHP5270-ifosfamide.htm" title="IFOSFAMIDE">IFOSFAMIDE</a></li><li id="_PHP5272-lomustine"><a href="PHP5272-lomustine.htm" title="LOMUSTINE">LOMUSTINE</a></li><li id="_PHP5274-melphalan"><a href="PHP5274-melphalan.htm" title="MELPHALAN">MELPHALAN</a></li><li id="_PHP5276-thiotepa"><a href="PHP5276-thiotepa.htm" title="THIOTEPA">THIOTEPA</a></li><li id="_PHP5279-treosulfan"><a href="PHP5279-treosulfan.htm" title="TREOSULFAN">TREOSULFAN</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP5234-mesna.htm">Previous: MESNA</a> | <a class="top" href="PHP5236-alkylating-drugs.htm#">Top</a> | <a accesskey="]" href="PHP5253-bendamustine-hydrochloride.htm">Next: BENDAMUSTINE HYDROCHLORIDE</a> ►</div></div></div></div><div id="pF"><div id="p2"><div id="pL"><div class="p4"><h2>Keep in touch</h2><ul><li><a href="http://www.pharmpress.com/?utm_source=medicinescomplete&amp;utm_medium=footer&amp;utm_campaign=medicinescomplete-referral">Pharmaceutical Press</a></li><li><a href="http://www.rpharms.com/">Royal Pharmaceutical Society</a></li><li><a href="http://www.pharmpress.com/mc-alerts.asp?utm_source=medicinescomplete&amp;utm_medium=footer&amp;utm_campaign=medicinescomplete-referral">Sign up for our eNewsletter</a></li><li><a href="http://twitter.com/#!/PharmPress/" class="p5"><img src="../../images/twitter.png" alt="Twitter logo" />Follow us on Twitter
              </a></li><li><a href="http://www.facebook.com/pages/Pharmaceutical-Press/296104187066918" class="p5"><img src="../../images/facebook.png" alt="Facebook logo" />Find us on Facebook
              </a></li></ul></div><div class="p4"><h2>Help and Support</h2><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a></li><li><a href="http://www.medicinescomplete.com/about/contact.htm">Contact Us</a></li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a></li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a></li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div><div class="p4"><h2>Provided for</h2><div id="cL"><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2013.  All rights reserved.</a></p><p><a href="http://www.medicinescomplete.com/mc/copyright.htm">MedicinesComplete © The Pharmaceutical Press 2013</a></p></div></div></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>